On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s (NYSE:JNJ) IMAAVY (nipocalimab-aahu) to treat warm autoimmune hemolytic anemia (wAIHA).
New Therapy for Rare Autoantibody Disease
The agency cleared the medication for adults and pediatric patients aged 12 and older who currently receive or previously received corticosteroids.
Following a Priority Review, IMAAVY stands as the very first therapy specifically proven safe and effective for this rare, life-threatening condition.
In patients suffering from wAIHA, pathogenic immunoglobulin G (IgG) autoantibodies attach to and destroy healthy red blood cells. This destructive process causes severe anemia, profound fatigue, and an elevated risk of morbidity and mortality.
